Intracellular signal transduction and modification of the tumor microenvironment induced by RET/ptcs in papillary thyroid carcinoma

Frontiers in Endocrinology

Volumn 3, Issue MAY, 2012, Pages

  Menicali, Elisa ^a   Moretti, Sonia ^a   Voce, Pasquale ^a   Romagnoli, Serena ^a   Avenia, Nicola ^a   Puxeddu, Efisio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Papillary thyroid carcinoma; RET PTC; Thyroid carcinoma

Indexed keywords

EID: 84874488646     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00067     Document Type: Review

References (223)

1. Anders, J., Kjar, S., and Ibáñez, C. F. (2001). Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J. Biol. Chem. 276, 35808-35817.
2. Andreozzi, F., Melillo, R. M., Carlo-magno, F., Oriente, F., Miele, C., Fiory, F., Santopietro, S., Castel-lone, M. D., Beguinot, F., San-toro, M., and Formisano, P. (2003). Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. Oncogene 22, 2942-2949.
3. Arlt, M. F., Durkin, S. G., Ragland, R. L., and Glover, T. W. (2006). Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst.) 5, 1126-1135.
4. Ashkar, S., Weber, G. F., Panout-sakopoulou, V., Sanchirico, M. E., Jansson, M., Zawaideh, S., Rittling, S. R., Denhardt, D. T., Glimcher, M. J., and Cantor, H. (2000). Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287, 860-864.
5. Adeniran, A. J., Zhu, Z., Gandhi, M., Steward, D. L., Fidler, J. P., Giordano, T. J., Biddinger, P. W., and Nikiforov, Y. E. (2006). Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 30, 216-222.
6. Balkwill, F., Charles, K. A., and Man-tovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217.
7. Balkwill, F., and Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet 357, 539-545.
8. Balter, M. (1996). Children become the first victims of fallout. Science 272, 357-360.
9. Bartolazzi, A., Gasbarri, A., Papotti, M., Bussolati, G., Lucante, T., Khan, A., Inohara, H., Marandino, F., Orlandi, F., Nardi, F., Vecchione, A., Tecce, R., Larsson, O., and Thyroid Cancer Study Group. (2001) Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357, 1644-1650.
10. Bleuer, J. P., Averkin, Y. I., and Abelin, T. (1997). Chernobyl-related thyroid cancer: what evidence for role of short-lived iodines? Environ. Health Perspect. 105, 1483-1486.
11. Bongarzone, I., Butti, M. G., Fugaz-zola, L., Pacini, F., Pinchera, A., Vorontsova, T. V., Demidchik, E. P., and Pierotti, M. A. (1997). Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 onco-gene in sporadic and in radiation-associated papillary thyroid carcinomas. Genomics 42, 252-259.
12. Bongarzone, I., Fugazzola, L., Vigneri, P., Mariani, L., Mondellini, P., Pacini, F., Basolo, F., Pinchera, A., Pilotti, S., and Pierotti, M. A. (1996). Age-related activation of the tyro-sine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 81, 2006-2009.
13. Bongarzone, I., Monzini, N., Borrello, M. G., Carcano, C., Ferraresi, G., Arighi, E., Mondellini, P., Della Porta, G., and Pierotti, M. A. (1993). Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol. Cell Biol. 13, 358-366.
14. Bongarzone, I., Vigneri, P., Mariani, L., Collini, P., Pilotti, S., and Pierotti, M.A. (1998). RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin. Cancer Res. 4, 223-228.
15. Borrello, M. G., Alberti, L., Fischer, A., Degl'innocenti, D., Ferrario, C., Gariboldi, M., Marchesi, F., Allavena, P., Greco, A., Collini, P., Pilotti, S., Cassinelli, G., Bressan, P., Fugazzola, L., Mantovani, A., and Pierotti, M. A. (2005). Induction of a proinflam-matory program in normal human thyrocytes by the RET/PTC1 onco-gene. Proc. Natl. Acad. Sci. U.S.A. 102, 14825-14830.
16. Bounacer, A., Wicker, R., Caillou, B., Cailleux, A. F., Sarasin, A., Schlum-berger, M., and Suárez, H. G. (1997). High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15, 1263-1273.
17. Bousquet, M., Quelen, C., De Mas, V., Duchayne, E., Roquefeuil, B., Delsol, G., Laurent, G., Dastugue, N., and Brousset, P. (2005). The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24, 7248-7252.
18. Bryant, P. E., and Riches, A. C. (1989). Oncogenic transformation of murine C3H 10T1/2 cells resulting from DNA double-strand breaks induced by a restriction endonucle-ase. Br. J. Cancer 60, 852-854.
19. Burrow, A. A., Williams, L. E., Pierce, L. C., and Wang, Y. H. (2009). Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics 10, 59. doi:10.1186/1471-2164-10-59
20. Cahill, S., Smyth, P., Finn, S. P., Denning, K., Flavin, R., O'Regan, E. M., Li, J., Potratz, A., Guenther, S. M., Henfrey, R., O'Leary, J. J., and Sheils, O. (2006). Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol. Cancer 5, 70.
21. Carlomagno, F., Salvatore, G., Cirafici, A. M., De Vita, G., Melillo, R. M., de Franciscis, V., Billaud, M., Fusco, A., and Santoro, M. (1997). The different ret-activating capability of mutations of cysteine 620 or cys-teine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res. 57, 391-395.
22. Carta, C., Moretti, S., Passeri, L., Barbi, F., Avenia, N., Cavaliere, A., Mona-celli, M., Macchiarulo, A., Santeu-sanio, F., Tartaglia, M., and Puxeddu,E. (2006). Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599Ins)). Clin. Endocrinol. (Oxf.) 64, 105-109.
23. Castellone, M. D., Guarino, V., De Falco, V., Carlomagno, F., Basolo, F., Faviana, P., Kruhoffer, M., Orntoft, T., Russell, J. P., Rothstein, J. L., Fusco, A., Santoro, M., and Melillo, R. M. (2004). Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 23, 5958-5967.
24. Castellone, M. D., and Santoro, M. (2008). Dysregulated RET signaling in thyroid cancer. Endocrinol. Metab. Clin. North Am. 37, 363-374.
25. Caudill, C. M., Zhu, Z., Ciampi, R., Stringer, J. R., and Nikiforov, Y. E. (2005). Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J. Clin. Endocrinol. Metab. 90, 2364-2369.
26. Celetti, A., Cerrato, A., Merolla, F., Vitagliano, D., Vecchio, G., and Grieco, M. (2004). H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene 23, 109-121.
27. Cetta, F., Chiappetta, G., Melillo, R. M., Petracci, M., Montalto, G., San-toro, M., and Fusco, A. (1998). The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. J. Clin. Endocrinol. Metab. 83, 1003-1006.
28. Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C., Rittling, S. R., Den-hardt, D. T., Sobel, R. A., Lock, C., Karpuj, M., Pedotti, R., Heller, R., Oksenberg, J. R., and Steinman, L. (2001). The influence of the proin-flammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294, 1731-1735.
29. Chappuis-Flament, S., Pasini, A.,and De Vita, G. (1998). MEN 2 mutations affecting specific extracytoplasmic cysteines exert a dual effect on the ret receptor. Oncogene 17, 2851-2861.
30. Cheung, C. C., Ezzat, S., Ramyar, L., Freeman, J. L., and Asa, S. L. (2000). Molecular basis off hurthle cell papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 85, 878-882.
31. Chiappetta, G., Toti, P., Cetta, F., Giu-liano, A., Pentimalli, F., Amendola, I., Lazzi, S., Monaco, M., Maz-zuchelli, L., Tosi, P., Santoro, M., and Fusco, A. (2002). The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J. Clin. Endocrinol. Metab. 87, 364-369.
32. Chua, E. L., Wu, W. M., Tran, K. T., McCarthy, S. W., Lauer, C. S., Dubourdieu, D., Packham, N., O'Brien, C. J., Turtle, J. R., and Dong, Q. (2000). Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J. Clin. Endocrinol. Metab. 85, 2733-2739.
33. Coquelle, A., Toledo, F., Stern, S., Bieth, A., and Debatisse, M. (1998). A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol. Cell 2, 259-265.
34. Coussens, L. M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867.
35. Croyle, M., Akeno, N., Knauf, J. A., Fabbro, D., Chen, X., Baumgart-ner, J. E., Lane, H. A., and Fagin, J. A. (2008). RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 68, 4183-4191.
36. Dailey, M. E., Lindsay, S., and Ska-hen, R. (1955). Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. Arch. Surg. 70, 291-297.
37. De Falco, V., Castellone, M. D., De Vita, G., Cirafici, A. M., Hersh-man, J. M., Guerrero, C., Fusco, A., Melillo, R. M., and Santoro, M. (2007). RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. Cancer Res. 67, 381-390.
38. de Visser, K. E., Eichten, A., and Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24-37.
39. Donatello, S., Fiorino, A., Degl'Innocenti, D., Alberti, L., Miranda, C., Gorla, L., Bongarzone, I., Rizzetti, M. G., Pierotti, M. A., and Borrello, M. G. (2007). SH2B1beta adaptor is a key enhancer of RET tyrosine kinase signaling. Oncogene 26, 6546-6559.
40. Ducut Sigala, J. L., Bottero, V., Young, D. B., Shevchenko, A., Mercurio,F., and Verma, I. M. (2004). Activation of transcription factor NF-kappaB requires ELKS, an IkappaB kinase regulatory subunit. Science 304, 1963-1967.
41. Dupont, S., Zacchigna, L., Cordenonsi, M., Soligo, S., Adorno, M., Rugge, M., and Piccolo, S. (2005). Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell 121, 87-99.
42. Durbec, P., Marcos-Gutierrez, C. V., Kilkenny, C., Grigoriou, M., Wartiowaara, K., Suvanto, P., Smith, D., Ponder, B., Costantini, F., and Saarma, M. (1996). GDNF signalling through the Ret receptor tyrosine kinase. Nature 381, 789-793.
43. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188.
44. Edwards, A. A. (2002). Modelling radiation-induced chromosome aberrations. Int. J. Radiat. Biol. 78, 551-558.
45. Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., Miccoli, P., Berti, P., Pacini, F., and Pinchera, A. (2008). Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 93, 682-687.
46. Elisei, R., Romei, C., Vorontsova, T., Cosci, B., Veremeychik, V., Kuchin-skaya, E., Basolo, F., Demidchik, E. P., Miccoli, P., Pinchera, A., and Pacini, F. (2001). RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab. 86, 3211-3216.
47. Eng, C., Clayton, D., Schuffenecker, I., Lenoir, G., Cote, G., Gagel, R. F., van Amstel, H. K., Lips, C. J., Nishisho, I., Takai, S. I., Marsh, D. J., Robinson, B. G., Frank-Raue, K., Raue, F., Xue, F., Noll, W. W., Romei, C., Pacini, F., Fink, M., Niederle, B., Zedenius, J., Nordenskjöld, M., Komminoth, P., Hendy, G. N., Mulligan, L. M., Gharib, H., Thibodeau, S. N., Lacroix, A., Frilling, A., and Ponder, B.A. J. (1996). The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International Ret Mutation Consortium. JAMA 276, 1575-1579.
48. Ermak, G., Jennings, T., Robinson, L., Ross, J. S., and Figge, J. (1996).Restricted patterns of CD44 variant exon expression in human papillary thyroid carcinoma. Cancer Res. 56, 1037-1042.
49. Evans, D. B., Shapiro, S. E., and Cote, G. J. (2007). Invited commentary: medullary thyroid cancer: the importance of RET testing. Surgery 141, 96-99.
50. Fenton, C. L., Lukes, Y., Nicholson, D., Dinauer, C. A., Francis, G. L., and Tuttle, R. M. (2000). The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J. Clin. Endocrinol. Metab. 85, 1170-1175.
51. Frêche, B., Guillaumot, P., Charmetant, J., Pelletier, L., Luquain, C., Christiansen, D., Billaud, M., and Manié, S. N. (2005). Inducible dimer-ization of RET reveals a specific AKT deregulation in onco-genic signaling. J. Biol. Chem. 280, 36584-36591.
52. Fugazzola, L., Pilotti, S., Pinchera, A., Vorontsova, T. V., Mondellini, P., Bongarzone, I., Greco,A.,Astakhova, L., Butti, M. G., Demidchik, E. P., Pacini, F., and Pierotti, M. A. (1995). Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 55, 5617-5620.
53. Fusco, A., Chiappetta, G., Hui, P., Garcia-Rostan, G., Golden, L., Kinder, B. K., Dillon, D. A., Giu-liano, A., Cirafici, A. M., Santoro, M., Rosai, J., and Tallini, G. (2002). Assessment of RET/PTC onco-gene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am. J. Pathol. 160, 2157-2167.
54. Fusco, A., Grieco, M., Santoro, M., Berlingieri, M. T., Pilotti, S., Pierotti, M. A., Della Porta, G., and Vec-chio, G. (1987). A new oncogene in humanthyroid papillarycarcinomas and their lymph-nodal metastases. Nature 328, 170-172.
55. Gacy, A. M., Goellner, G., Juranic, N., Macura, S., and McMurray, C. T. (1995). Trinucleotide repeats that expand in human disease form hairpin structures in vitro. Cell 81, 533-540.
56. Gallina, G., Dolcetti, L., Serafini, P., De Santo,C., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., Bicciato, S., and Bronte, V. (2006). Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116, 2777-2790.
57. Gandhi, M., Dillon, L. W., Pramanik, S., Nikiforov, Y. E., and Wang, Y. H. (2010). DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene 29, 2272-2280.
58. Gandhi, M., Medvedovic, M., Stringer, J. R., and Nikiforov, Y. E. (2006). Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 25, 2360-2366.
59. Gandhi, M. S., Stringer, J. R., Niki-forova, M. N., Medvedovic, M., and Nikiforov, Y. E. (2009). Gene position within chromosome territories correlates with their involvement in distinct rearrangement types in thyroid cancer cells. Genes Chromosomes Cancer 48, 222-228.
60. Gasparini, P., Sozzi, G., and Pierotti, M. A. (2007). The role of chromosomal alterations in human cancer development. J. Cell. Biochem. 102, 320-331.
61. Geissinger, E., Weisser, C., Fischer, P., Schartl, M., and Wellbrock, C. (2002). Autocrine stimulation by osteopontin contributes to anti-apoptotic signalling of melanocytes in dermal collagen. Cancer Res. 62, 4820-4828.
62. Ghosh, S., and Karin, M. (2002). Missing pieces in the NF-kappaB puzzle. Cell 109, 81-96.
63. Gimm, O., Marsh, D. J., Andrew, S. D., Frilling, A., Dahia, P. L., Mulligan, L. M., Zajac, J. D., Robinson, B. G., and Eng, C. (1997). Germline din-ucleotide mutation in codon 883 of the ret proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J. Clin. Endocrinol. Metab. 82, 3902-3904.
64. Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bon-garzone, I., Pierotti, M. A., Della Porta, G., Fusco, A., and Vecchio, G. (1990). PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60, 557-563.
65. Griffin, K. J., Kirschner, L. S., Matyakhina, L., Stergiopoulos, S. G., Robinson-White, A., Lenherr, S. M., Weinberg, F. D., Claflin, E. S., Batista, D., Bourdeau, I., Voutetakis, A., Sandrini, F., Meoli, E. M., Bauer, A. J., Cho-Chung, Y. S., Bornstein, S. R., Carney, J. A., and Stratakis, C. A. (2004). A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1Ainduced lesions. J. Med. Genet. 41, 923-931.
66. Guarino, V., Faviana, P., Salvatore, G., Castellone, M. D., Cirafici, A. M., De Falco, V., Celetti, A., Giannini, R., Basolo, F., Melillo, R. M., and Santoro, M. (2005). Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasive-ness. J. Clin. Endocrinol. Metab. 90, 5270-5278.
67. Gujral, T. S., Singh, V. K., Jia, Z., and Mulligan, L. M. (2006). Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res. 66, 10741-10749.
68. Hamatani, K., Eguchi, H., Ito, R., Mukai, M., Takahashi, K., Taga, M., Imai, K., Cologne, J., Soda, M., Arihiro, K., Fujihara, M., Abe, K., Hayashi, T., Nakashima, M., Sekine, I., Yasui, W., Hayashi, Y., and Nakachi, K. (2008). RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res. 68, 7176-7182.
69. Handt, O., Sutherland, G. R., and Richards, R. I. (2000). Fragile sites and minisatellite repeat instability. Mol. Genet. Metab. 70, 99-105.
70. Hayashi, H., Ichihara, M., Iwashita, T., Murakami, H., Shimono, Y., Kawai, K., Kurokawa, K., Murakumo, Y., Imai, T., Funahashi, H., Nakao, A., and Takahashi, M. (2000). Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19, 4469-4475.
71. He, W., Dorn, D. C., Erdjument-Bromage, H., Tempst, P., Moore, M. A., and Massagué, J. (2006). Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell 125, 929-941.
72. Hellman, A., Rahat, A., Scherer, S. W., Darvasi, A., Tsui, L. C., and Kerem, B. (2000). Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol. Cell Biol. 20, 4420-4427.
73. Hewett, D. R., Handt, O., Hobson, L., Mangelsdorf, M., Eyre, H. J., Baker, E., Sutherland, G. R., Schuffenhauer, S., Mao, J. I., and Richards, R. I. (1998). FRA10B structure reveals common elements in repeat expansion and chromosomal fragile site genesis. Mol. Cell 1, 773-781.
74. Hlatky, L., Sachs, R. K., Vazquez, M., and Cornforth, M. N. (2002). Radiation-induced chromosome aberrations: insights gained from biophysical modeling. Bioessays 24, 714-723.
75. Hwang, E. S., Kim, D. W., Hwang, J. H., Jung, H. S., Suh, J. M., Park, Y. J., Chung, H. K., Song, J. H., Park, K. C., Park, S. H., Yun, H. J., Kim, J. M., and Shong, M. (2004). Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases. Mol. Endocrinol. 18, 2672-2684.
76. Hwang, J. H., Kim, D. W., Suh, J. M., Kim, H., Song, J. H., Hwang, E. S., Park, K. C., Chung, H. K., Kim, J. M., Lee, T. H., Yu, D. Y., and Shong, M. (2003). Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Mol. Endocrinol. 17, 1155-1166.
77. Iervolino, A., Iuliano, R., Trapasso, F., Viglietto, G., Melillo, R. M., Carlo-magno, F., Santoro, M., and Fusco, A. (2006). The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Res. 66, 6280-6287.
78. Ito, S., Iwashita, T., Asai, N., Murakami, H., Iwata, Y., Sobue, G., and Takahashi, M. (1997). Biological properties of ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschprung's disease pheno-type. Cancer Res. 57, 2870-2872.
79. Ito, T., Seyama, T., Iwamoto, K. S., Hayashi, T., Mizuno, T., Tsuyama, N., Dohi, K., Nakamura, N., and Akiyama, M. (1993) In vitro irradiation is able to cause RET onco-gene rearrangement. Cancer Res. 53, 2940-2943.
80. Jain, S., Encinas, M., Johnson, E. M. Jr., and Milbrandt, J. (2006). Critical and distinct roles for key RET tyrosine docking sites in renal development. Genes Dev. 20, 321-333.
81. Jhiang, S. M., Caruso, D. R., Gilmore, E., Ishizaka, Y., Tahira, T., Nagao, M., Chiu, I. M., and Mazzaferri, E. L. (1992). Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene 7, 1331-1337.
82. Jhiang, S. M., Sagartz, J. E., Tong, Q., Parker-Thornburg, J., Capen, C. C., Cho, J. Y., Xing, S., and Ledent, C. (1996). Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137, 375-378.
83. Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., and Fagin, J. A. (2003). High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457.
84. Kirschner, L. S., Sandrini, F., Monbo, J., Lin, J. P., Carney, J. A., and Stratakis, C. A. (2000). Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum. Mol. Genet.9, 3037-3046.
85. Klugbauer, S., Pfeiffer, P., Gassenhu-ber, H., Beimfohr, C., and Rabes, H. M. (2001). RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics 73, 149-160.
86. Knauf, J. A., Kuroda, H., Basu, S., and Fagin, J. A. (2003). RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22, 4406-4412.
87. Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X. H., Refetoff, S., Nikiforov, Y. E., and Fagin, J. A. (2005). Targeted expression of BRAF(V600E) in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65, 4238-4245.
88. Knowles, P. P., Murray-Rust, J., Kjaer, S., Scott, R. P., Hanrahan, S., Santoro, M., Ibáñez, C. F., and McDonald, N. Q. (2006). Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 281, 33577-33587.
89. Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., Iwakawa, R., Ogi-wara, H., Oike, T., Enari, M., Schet-ter, A. J., Okayama, H., Haugen, A., Skaug, V., Chiku, S., Yamanaka, I., Arai, Y., Watanabe, S., Sekine, I., Ogawa, S., Harris, C. C., Tsuda, H., Yoshida, T., Yokota, J., and Shibata, T. (2011). KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 18, 375-377.
90. Koki, A., Khan, N. K., Woerner, B. M., Dannenberg, A. J., Olson, L., Seibert, K., Edwards, D., Hardy, M., Isakson, P., and Masferrer, J. L. (2002). Cyclooxygenase-2 in humanpathological disease. Adv. Exp. Med. Biol. 507, 177-184.
91. Kondo, T., Ezzat, S., and Asa, S. L. (2006). Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 6, 292-306.
92. Kouvaraki, M. A., Shapiro, S. E., Per-rier, N. D., Cote, G. J., Gagel, R. F., Hoff, A. O., Sherman, S. I., Lee, J. E., and Evans, D. B. (2005). RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15, 531-544.
93. Krützfeldt, M., Ellis, M., Weekes, D. B., Bull, J. J., Eilers, M., Vivanco, M. D., Sellers, W. R., and Mit-tnacht, S. (2005). Selective ablation of retinoblastoma protein function by the RET finger protein. Mol. Cell 18, 213-224.
94. Kulkarni, S., Heath, C., Parker, S., Chase, A., Iqbal, S., Pocock, C. F., Kaeda, J., Cwynarski, K., Goldman, J. M., and Cross, N. C. (2000). Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res. 60, 3592-3598.
95. Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E., Janisch, L., Nauling, F., Hong, D. S., Ng, C. S., Ye, L., Gagel, R. F., Frye, J., Müller, T., Ratain, M. J., and Salgia, R. (2011). Activity of XL184 (Cabozantinib), an oral tyro-sine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29, 2660-2666.
96. Kuwano, A., and Kajii, T. (1987). Syn-ergistic effect of aphidicolin and ethanol on the induction of common fragile sites. Hum. Genet. 75, 75-78.
97. Lam, A. K., Montone, K. T., Nolan, K. A., and Livolsi, V. A. (1998). Ret onco-gene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Hum. Pathol. 29, 565-568.
98. Learoyd, D. L., Messina, M., Zedenius, J., Guinea, A. I., Delbridge, L. W., and Robinson, B. G. (1998). RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 83, 3631-3635.
99. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., and Davis, M. M. (1999). Characterization of circulating T cells specific for tumor-associated antigensin melanoma patients. Nat. Med. 5, 677-685.
100. Leone, V., Mansueto, G., Pierantoni, G. M., Tornincasa, M., Merolla, F., Cerrato, A., Santoro, M., Grieco, M., Scaloni, A., Celetti, A., and Fusco, A. (2010). CCDC6 represses CREB1 activity by recruiting his-tone deacetylase 1 and protein phos-phatase 1. Oncogene 29, 4341-4351.
101. Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom,T.,Brennan,K. W.,Donahue, A., Downing, S. R., Frampton, G. M., Garcia, L., Juhn, F., Mitchell, K. C., White, E., White, J., Zwirko, Z., Peretz, T., Nechushtan, H., Soussan-Gutman, L., Kim, J., Sasaki, H., Kim, H. R., Park, S. I., Ercan, D., Shee-han, C. E., Ross, J. S., Cronin, M. T., Jänne, P. A., and Stephens, P. J. (2011). Identification of new ALK and RET gene fusions from colorec-tal and lung cancer biopsies. Nat. Med. 18, 382-384.
102. Ludwig, L., Kessler, H., Wagner, M., Hoang-Vu, C., Dralle, H., Adler, G., Böhm, B. O., and Schmid, R. M. (2001). Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res. 61, 4526-4535.
103. Luster, A. D. (1998). Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338, 436-445.
104. Mancini, J. A., Blood, K., Guay, J., Gordon, R., Claveau, D., Chan, C. C., and Riendeau, D. (2001). Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J. Biol. Chem. 276, 4469-4475.
105. Matsubayashi, S., Kawai, K., Mat-sumoto, Y., Mukuta, T., Morita, T., Hirai, K., Matsuzuka, F., Kakudoh, K., Kuma, K., and Tamai, H. (1995). The correlation between papillary thyroid carcinoma and lympho-cytic infiltration in the thyroid gland. J. Clin. Endocrinol. Metab. 80, 3421-3424.
106. Matter, N., Herrlich, P., and König, H. (2002). Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420, 691-695.
107. Mayr, B., Brabant, G., Goretzki, P., Rüschoff, J., Dietmaier, W., and Dralle, H. (1997). Ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J. Clin. Endocrinol. Metab. 82, 1306-1307.
108. Melillo, R. M., Castellone, M. D., Guar-ino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., Orntoft, T., Fusco, A., and Santoro, M. (2005). The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115, 1068-1081.
109. Mellado, M., Rodríguez-Frade, J. M., Mañes, S., and Martínez-A, C. (2001). Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu. Rev. Immunol. 19, 397-421.
110. Mesa, C. Jr., Mirza, M., Mitsutake, N., Sartor, M., Medvedovic, M., Tom-linson, C., Knauf, J. A., Weber, G. F., and Fagin, J. A. (2006). Conditional activation of RET/PTC3 and BRAF(V600E) in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res. 66, 6521-6529.
111. Minoletti, F., Butti, M. G., Coronelli, S., Miozzo, M., Sozzi, G., Pilotti, S., Tunnacliffe, A., Pierotti, M. A., and Bongarzone, I. (1994). The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2. Genes Chromosomes Cancer 11, 51-57.
112. Mishmar, D., Rahat, A., Scherer, S. W., Nyakatura, G., Hinzmann, B., Kohwi, Y., Mandel-Gutfroind, Y., Lee, J. R., Drescher, B., Sas, D. E., Margalit, H., Platzer, M., Weiss, A., Tsui, L. C., Rosenthal, A., and Kerem, B. (1998). Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc. Natl. Acad. Sci. U.S.A. 95, 8141-8146.
113. Mizuno, T., Iwamoto, K. S., Kyoizumi, S., Nagamura, H., Shinohara, T., Koyama, K., Seyama, T., and Hamatani, K. (2000). Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene 19, 438-443.
114. Mizuno, T., Kyoizumi, S., Suzuki, T., Iwamoto, K. S., and Seyama, T. (1997). Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogen-esis. Oncogene 15, 1455-1460.
115. Monaco, C., Visconti, R., Barone, M. V., Pierantoni, G. M., Berlingieri, M. T., De Lorenzo, C., Mineo, A., Vecchio, G., Fusco, A., and Santoro, M. (2001). The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3oncoprotein to the plasma membrane. Oncogene 20, 599-608.
116. Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., Kollias, G., and Balkwill, F. (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 5, 828-831.
117. Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L., Mohar, A., Verástegui, E., and Zlot-nik, A. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56.
118. Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., Neumann, H. P. H., Thibodeau, S. N., and Ponder, B. A. J. (1994). Specific mutations of the ret proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet. 6, 70-74.
119. Murakami, M., Nakashima, K., Kamei, D., Masuda, S., Ishikawa, Y., Ishii, T., Ohmiya,Y.,Watanabe,K., and Kudo, I. (2003). Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J. Biol. Chem. 278, 37937-37947.
120. Murakami, M., Naraba, H., Tanioka, T., Semmyo,N.,Nakatani,Y.,Kojima,F., Ikeda, T., Fueki, M., Ueno, A., Oh, S., and Kudo, I. (2000). Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 275, 32783-32792.
121. Musio, A., and Sbrana, I. (1997). Aphidicolin-sensitive specific common fragile sites: a biomarker of exposure to pesticides. Environ. Mol. Mutagen. 29, 250-255.
122. Nikiforov, Y. E. (2002). RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 13, 3-16.
123. Nikiforov, Y. E. (2004). Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr. Pathol. 15, 319-327.
124. Nikiforov, Y. E. (2011). Molecular diagnostics of thyroid tumors. Arch. Pathol. Lab. Med. 135, 569-577.
125. Nikiforov, Y. E., Koshoffer, A., Niki-forova, M., Stringer, J., and Fagin, J. A. (1999). Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-inducedthyroid carcinomas. Oncogene 18, 6330-6334.
126. Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Munoz, H., and Fagin, J. A. (1997). Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57, 1690-1694.
127. Nikiforova, M. N., Caudill, C. M., Bid-dinger,P., and Nikiforov,Y. E. (2002). Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int. J. Surg. Pathol. 10, 15-22.
128. Nikiforova, M. N., Stringer, J. R., Blough, R., Medvedovic, M., Fagin, J. A., and Nikiforov, Y. E. (2000). Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290, 138-141.
129. Nose, F., Ichikawa, T., Fujiwara, M., and Okayasu, I. (2002). Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase. Am. J. Clin. Pathol. 117, 546-551.
130. Olumi, A. F., Grossfeld, G. D., Hayward, S. W., Carroll, P. R., Tlsty, T. D., and Cunha, G. R. (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human pro-static epithelium. Cancer Res. 59, 5002-5011.
131. Palakodeti, A., Han, Y., Jiang, Y., and Le Beau, M. M. (2004). The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer 39, 71-76.
132. Papotti, M., Volante, M., Giuliano, A., Fassina, A., Fusco, A., Bussolati, G., Santoro, M., and Chiappetta, G. (2000). RET/PTC activation in hyalinizing trabecular tumors of the thyroid. Am. J. Surg. Pathol. 24, 1615-1621.
133. Pelliccia, F., Bosco, N., Curatolo, A., and Rocchi, A. (2008). Replication timing of two human common fragile sites: FRA1H and FRA2G. Cytogenet. Genome Res. 121, 196-200.
134. Pierotti, M. A., Santoro, M., Jenkins, R. B., Sozzi, G., Bongarzone, I., Grieco, M., Monzini, N., Miozzo, M., Herrmann, M. A., and Fusco, A. (1992). Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc. Natl. Acad. Sci. U.S.A. 89, 1616-1620.
135. Ponta, H., Sherman, L., and Herrlich, P. A. (2003). CD44: from adhesionmolecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 4, 33-45.
136. Powell, D. J. Jr., Eisenlohr, L. C., and Rothstein, J. L. (2003). A thyroid tumor-specific antigen formed by the fusion of two self proteins. J. Immunol. 170, 861-869.
137. Powell, D. J. Jr., Russell, J., Nibu, K., Li, G., Rhee, E., Liao, M., Goldstein, M., Keane, W. M., Santoro, M., Fusco, A., and Rothstein,J. L. (1998). The RET/PTC3 oncogene: metasta-tic solid-type papillary carcinomas in murine thyroids. Cancer Res. 58, 5523-5528.
138. Pufnock, J. S., and Rothstein, J. L. (2009). Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J. Immunol. 182, 5498-5506.
139. Puxeddu, E., and Fagin, J. A. (2001). Genetic markers in thyroid neopla-sia. Endocrinol. Metab. Clin. North Am. 30, 493-513.
140. Puxeddu, E., Knauf, J. A., Sartor, M. A., Mitsutake, N., Smith, E. P., Medvedovic, M., Tomlinson, C. R., Moretti, S., and Fagin, J. A. (2005a). RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr. Relat. Cancer 12, 319-334.
141. Puxeddu, E., Zhao, G., Stringer, J. R., Medvedovic, M., Moretti, S., and Fagin, J. A. (2005b). Characterization of novel non-clonal intrachro-mosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. Mutat. Res. 570, 17-32.
142. Puxeddu, E., Mitsutake, N., Knauf, J. A., Moretti, S., Kim, H. W., Seta, K. A., Brockman, D., Myatt, L., Millhorn, D. E., and Fagin,J.A. (2003a). Micro-somal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway. J. Biol. Chem. 278, 52131-52138.
143. Puxeddu, E., Moretti, S., Giannico, A., Martinelli, M., Marino, C., Avenia, N., Cristofani, R., Farabi, R., Reboldi, G., Ribacchi, R., Pontecorvi, A., and Santeusanio, F. (2003b). Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur. J. Endocrinol. 148, 505-513.
144. Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E. D., Fadda, G., Cavaliere, A., Ribacchi, R., Falorni, A., Pontecorvi, A., Pacini, F., Pinchera, A., and Santeusanio, F. (2004). BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 89, 2414-2420.
145. Puxeddu, E., Romagnoli, S., and Dot-torini, M. E. (2011). Targeted therapies for advanced thyroid cancer. Curr. Opin. Oncol. 23, 13-21.
146. Rabes, H. M., Demidchik, E. P., Sidorow, J. D., Lengfelder, E., Beimfohr, C., Hoelzel, D., and Klugbauer, S. (2000). Pattern of radiation-induced RET andNTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res. 6, 1093-1103.
147. Rhoden, K. J., Unger, K., Salvatore, G., Yilmaz, Y., Vovk, V., Chiap-petta, G., Qumsiyeh, M. B., Roth-stein, J. L., Fusco, A., Santoro, M., Zitzelsberger, H., and Tallini, G. (2006). RET/papillary thyroid cancer rearrangement in nonneoplas-tic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J. Clin. Endocrinol. Metab. 91, 2414-2423.
148. Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera,M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., Ghossein, R. A., and Fagin, J. A. (2009). Muta-tional profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 69, 4885-4893.
149. Richardson, D. S., Gujral, T. S., Peng, S., Asa, S. L., and Mulligan, L. M. (2009). Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins. Cancer Res. 69, 4861-4869.
150. Rittling, S. R., and Chambers, A. F. (2004). Role of osteopontin in tumour progression. Br. J. Cancer 90, 1877-1881.
151. Robinson, B. G., Paz-Ares, L., Krebs, A., Vasselli, J., and Haddad, R. (2010). Vandetanib (100mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 95, 2664-2671.
152. Romei, C., Elisei, R., Pinchera, A., Cec-cherini, I., Molinaro, E., Mancusi, F., Martino, E., Romeo, G., and Pacini, F. (1996). Somatic mutations of the ret proto-oncogene in sporadic medullarythyroidcarcinomaarenot restricted to exon 16 and are associated with tumor recurrence. J. Clin. Endocrinol. Metab. 81, 1619-1622.
153. Ron, E., Lubin, J. H., Shore, R. E., Mabuchi, K., Modan, B., Pottern, L. M., Schneider, A. B., Tucker, M. A., and Boice, J. D. Jr. (1995). Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat. Res. 141, 259-277.
154. Rosai, J., Carcangiu, M. L., and DeLellis, R. A. (1992). Atlas of Tumor Pathology: Tumors of the Thyroid Gland, 3rd Series. Washington, DC: Armed Forces Institute of Pathology.
155. Rosenberg, S. A. (1997). Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18, 175-182.
156. Rothkamm, K., Kühne, M., Jeggo, P. A., and Löbrich, M. (2001). Radiation-induced genomic rearrangements formed by nonhomologous end-joining of DNA double-strand breaks. Cancer Res. 61, 3886-3893.
157. Saad, A. G., Kumar, S., Ron, E., Lubin, J. H., Stanek, J., Bove, K. E., and Nikiforov, Y. E. (2006). Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J. Clin. Endocrinol. Metab. 91, 2672-2677.
158. Santoro, M., Carlomagno, F., Hay, I. D., Herrmann, M. A., Grieco, M., Melillo, R., Pierotti, M. A., Bon-garzone, I., Della Porta, G., and Berger, N. (1992). Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest. 89, 1517-1522.
159. Santoro, M., Carlomagno, F., Melillo, R. M., Billaud, M., Vecchio, G., and Fusco, A. (1999). Molecular mechanisms of ret activation in human neoplasia. J. Endocrinol. Invest. 22, 811-819.
160. Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., and Di Fiore, P. P. (1995). Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267, 381-383.
161. Santoro, M., Chiappetta, G., Cerrato, A., Salvatore, D., Zhang, L., Manzo, G., Picone, A., Portella, G., San-telli, G., Vecchio, G., and Fusco, A. (1996). Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12, 1821-1826.
162. Santoro, M., Dathan, N. A., Berlingieri, M. T., Bongarzone, I., Paulin, C., Grieco, M., Pierotti, M. A., Vecchio, G., and Fusco, A. (1994). Molecular characterization of RET/PTC3; anovel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9, 509-516.
163. Santoro, M., Melillo, R. M., and Fusco, A. (2006). RET/PTC activation in papillary thyroid carcinoma: European journal of endocrinology prize lecture. Eur. J. Endocrinol. 155, 645-653.
164. Santoro, M., Melillo, R. M., Grieco, M., Berlingieri, M. T., Vecchio, G., and Fusco, A. (1993). The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ. 4, 77-84.
165. Sariola, H., and Saarma, M. (2003). Novel functions and signalling pathways for GDNF. J. Cell. Sci. 116, 3855-3862.
166. Savage, J. R. (1998). A brief survey of aberration origin theories. Mutat. Res. 404, 139-147.
167. Scarpino, S., Stoppacciaro, A., Bal-lerini, F., Marchesi, M., Prat, M., Stella, M. C., Sozzani, S., Allavena, P., Mantovani, A., and Ruco, L. P. (2000). Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 156, 831-837.
168. Schlumberger, M., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J. P., Eschenberg, M. J., Sun, Y. N., Juan, T., Stepan, D. E., and Sherman, S. I. (2009). Phase II study of safety and efficacy of mote-sanib in patients with progressive or symptomatic, advanced or metasta-tic medullary thyroid cancer. J. Clin. Oncol. 27, 3794-3801.
169. Schuetz, G., Rosário, M., Grimm, J., Boeckers, T. M., Gundelfinger, E. D., and Birchmeier, W. (2004). The neu-ronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells. J. Cell Biol. 167, 945-952.
170. Schuringa, J. J., Wojtachnio, K., Hagens, W., Vellenga, E., Buys, C. H., Hofstra, R., and Kruijer, W. (2001). MEN2A-RET-induced cellular transformation by activation of STAT3. Onco-gene 20, 5350-5358.
171. Scotton, C. J., Wilson, J. L., Scott, K., Stamp, G., Wilbanks, G. D., Fricker, S., Bridger, G., and Balk-will, F. R. (2002). Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62, 5930-5938.
172. Segal, K., Ben-Bassat, M., Avraham, A., Har-El, G., and Sidi, J. (1985).Hashimoto's thyroiditis and carcinoma of the thyroid gland. Int. Surg. 70, 205-209.
173. Segouffin-Cariou, C., and Billaud, M. (2000). Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J. Biol. Chem. 275, 3568-3576.
174. Serafini, P., De Santo, C., Marigo, I., Cin-garlini, S., Dolcetti, L., Gallina, G., Zanovello, P., and Bronte, V. (2004). Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53, 64-72.
175. Shimono, Y., Murakami, H., Hasegawa, Y., and Takahashi, M. (2000). RET finger protein is a transcrip-tional repressor and interacts with enhancer of polycomb that has dual transcriptional functions. J. Biol. Chem. 275, 39411-39419.
176. Shrivastav, M., De Haro, L. P., and Nickoloff, J. A. (2008). Regulation of DNA double-strand break repair pathway choice. Cell Res. 18, 134-147.
177. Smanik, P. A., Furminger, T. L., Mazza-ferri, E. L., and Jhiang, S. M. (1995). Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma. Hum. Mol. Genet. 4, 2313-2318.
178. Smida, J., Salassidis, K., Hieber, L., Zitzelsberger, H., Kellerer, A. M., Demidchik, E. P., Negele, T., Spels-berg, F., Lengfelder, E., Werner, M., and Bauchinger, M. (1999). Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int. J. Cancer 80, 32-38.
179. Smith, D. P., Houghton, C., and Ponder, B. A. J. (1997). Germline mutation of ret codon 883 in two cases of de novo MEN 2B. Oncogene 15, 1213-1217.
180. Smith, W. L., and Langenbach, R. (2001). Why there are two cyclooxy-genase isozymes. J. Clin. Invest. 107, 1491-1495.
181. Soares, P., Fonseca, E., Wynford-Thomas, D., and Sobrinho-Simões, M. (1998). Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J. Pathol. 185, 71-78.
182. Specht, M. C., Tucker, O. N., Hocever, M., Gonzalez, D., Teng, L., and Fahey TJ, 3. r. d. (2002). Cyclooxygenase-2 expression in thyroid nodules. J. Clin. Endocrinol. Metab. 87, 358-363.
183. Stratakis, C. A., and Ball, D. W. (2000). A concise genetic and clinical guide to multiple endocrine neoplasias and related syndromes. J. Pediatr.Endocrinol. Metab. 13, 457-465.
184. Sugg, S. L., Ezzat, S., Rosen, I. B., Freeman, J. L., and Asa, S. L. (1998). Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab. 83, 4116-4122.
185. Sugg, S. L., Ezzat, S., Zheng, L., Freeman, J. L., Rosen, I. B., and Asa, S. L. (1999). Oncogene profile of papillary thyroid carcinoma. Surgery 125, 46-52.
186. Sugg, S. L., Zheng, L., Rosen, I. B., Freeman, J. L., Ezzat, S., and Asa, S. L. (1996). ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J. Clin. Endocrinol. Metab. 81, 3360-3365.
187. Sutherland, G. R. (1991). Chromosomal fragile sites. Genet. Anal. Tech. Appl. 8, 161-166.
188. Takahashi, K., Eguchi, H., Arihiro, K., Ito, R., Koyama, K., Soda, M., Cologne, J., Hayashi, Y., Nakata, Y., Nakachi, K., and Hamatani, K. (2007). The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol. Carcinog. 46, 242-248.
189. Takahashi, M., Ritz, J., and Cooper, G. M. (1985). Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42, 581-588.
190. Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka,R.,Hamanaka,W.,Ninomiya, H., Uehara, H., Lim Choi, Y., Satoh, Y., Okumura, S., Nakagawa, K., Mano, H., and Ishikawa, Y. (2011). RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18, 378-381.
191. Tallini, G., and Asa, S. L. (2001). RET oncogene activation in papillary thyroid carcinoma. Adv. Anat. Pathol. 8, 345-354.
192. Tallini, G.,Santoro, M.,Helie,M., Carlo-magno, F., Salvatore, G., Chiappetta, G., Carcangiu, M. L., and Fusco, A. (1998). RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor pheno-types. Clin. Cancer Res. 4, 287-294.
193. Tanikawa, N., Ohmiya, Y., Ohkubo, H., Hashimoto, K., Kangawa, K., Kojima, M., Ito, S., and Watanabe, K. (2002). Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem. Biophys. Res. Commun. 291, 884-889.
194. Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M., and Kudo, I. (2000). Molecular identification of cytosolic prostaglandin E2 syn-thase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 275, 32775-32782.
195. Thomas, G. A., Bunnell, H., Cook, H. A., Williams, E. D., Nerovnya, A., Cherstvoy, E. D., Tronko, N. D., Bogdanova, T. I., Chiappetta, G., Viglietto, G., Pentimalli, F., Salva-tore, G., Fusco, A., Santoro, M., and Vecchio, G. (1999). High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J. Clin. Endocrinol. Metab. 84, 4232-4238.
196. Tong, Q., Xing, S., and Jhiang, S. M. (1997). Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity. J. Biol. Chem. 272, 9043-9047.
197. Uchida, M., Enomoto, A., Fukuda, T., Kurokawa, K., Maeda, K., Kodama, Y., Asai, N., Hasegawa, T., Shi-mono, Y., Jijiwa, M., Ichihara, M., Murakumo, Y., and Taka-hashi, M. (2006). Dok-4 regulates GDNF-dependent neurite outgrowth through downstream activation of Rap1 and mitogen-activated protein kinase. J. Cell. Sci. 119, 3067-3077.
198. Usdin, K., and Woodford, K. J. (1995). CGG repeats associated with DNA instability and chromosome fragility form structures that block DNA synthesis in vitro. Nucleic Acids Res. 23, 4202-4209.
199. Van den Eynde, B., Lethé, B., Van Pel, A., De Plaen, E., and Boon, T. (1991). The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syn-geneic DBA/2 mice. J. Exp. Med. 173, 1373-1384.
200. Viglietto, G., Chiappetta, G., Martinez-Tello, F. J., Fukunaga, F. H., Tallini, G., Rigopoulou, D., Visconti, R., Mastro, A., Santoro, M., and Fusco, A. (1995). RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11, 1207-1210.
201. Visconti, R., Cerutti, J., Battista, S., Fedele, M., Trapasso, F., Zeki, K., Miano, M. P., de Nigris, F., Casalino, L., Curcio, F., Santoro, M., and Fusco, A. (1997). Expression of the neo-plastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 15, 1987-1994.
202. Vitagliano, D., Portella, G., Troncone, G., Francione, A., Rossi, C., Bruno,A., Giorgini, A., Coluzzi, S., Nappi, T. C., Rothstein, J. L., Pasquinelli, R., Chiappetta, G., Terracciano, D., Macchia, V., Melillo, R. M., Fusco, A., and Santoro, M. (2006). Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 25, 5467-5474.
203. Weber, G. F. (2001). The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta 1552, 61-85.
204. Wells, S. A. Jr., Gosnell, J. E., Gagel, R. F., Moley, J., Pfister, D., Sosa, J. A., Skinner, M., Krebs, A., Vasselli, J., and Schlumberger, M. (2010). Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28, 767-772.
205. Wells, S. A. Jr., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., San-toro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., Read, J., Lang-muir, P., Ryan, A. J., and Schlum-berger, M. J. (2012). Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134-141.
206. Wells, S. A. Jr., and Santoro, M. (2009). Targeting the RET pathway in thyroid cancer. Clin. Cancer Res. 15, 7119-7123.
207. Weterings, E., and Chen, D. J. (2008). The endless tale of non-homologous end-joining. Cell Res. 18, 114-124.
208. Williams, D. (2002). Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat. Rev. Cancer 2, 543-549.
209. Winegar, R. A., Lutze, L. H., Rufer, J. T., and Morgan, W. F. (1992). Spectrum of mutations produced by specific types of restriction enzyme-induced double-strand breaks. Mutagenesis 7, 439-445.
210. Winship, T., and Rosvoll, R. V. (1970). Cancer of the thyroid in children. Proc. Natl. Cancer Conf. 6, 677-681.
211. Wixted, J. H., Rothstein, J. L., and Eisenlohr, L. C. (2011). Identification of functionally distinct TRAF proinflammatory and PI3K/MEK transforming activities emanating from the RET/PTC fusion oncoprotein. J. Biol. Chem. 287, 3691-3703.
212. Wu, Z. H., Shi, Y., Tibbetts, R. S., and Miyamoto, S. (2006). Molecular linkage between the kinase ATM andNF-kappaB signaling in response to genotoxic stimuli. Science 311, 1141-1146.
213. Xing, M. (2010). Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol. Cell. Endocrinol. 321, 86-93.
214. Yates, B. L., and Morgan, W. F. (1993). Nonhomologous DNA end rejoining in chromosomal aberration formation. Mutat. Res. 285, 53-60.
215. Yoshimatsu, K., Golijanin, D., Paty, P. B., Soslow, R. A., Jakobsson, P. J., DeLel-lis, R. A., Subbaramaiah, K., and Dannenberg, A. J. (2001). Inducible microsomal prostaglandin E syn-thase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 7, 3971-3976.
216. Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., and Fu, Y. X. (2005). Intratu-mor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201, 779-791.
217. Yunis, J. J., and Soreng, A. L. (1984). Constitutive fragile sites and cancer. Science 226, 1199-1204.
218. Zhang, H., and Freudenreich, C. H. (2007). An AT-rich sequence in human commonfragilesiteFRA16D causes fork stalling and chromosome breakage in S. cerevisiae. Mol. Cell 27, 367-379.
219. Zhong, S., Delva, L., Rachez, C., Cen-ciarelli, C., Gandini, D., Zhang, H., Kalantry, S., Freedman, L. P., and Pandolfi, P. P. (1999). A RA-dependent, tumour-growth sup-pressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat. Genet. 23, 287-295.
220. Zhu, Z., Ciampi, R., Nikiforova, M. N., Gandhi, M., and Nikiforov, Y. E. (2006). Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91, 3603-3610.
221. Zlotorynski, E., Rahat,A., Skaug, J.,Ben-Porat, N., Ozeri, E., Hershberg, R., Levi, A., Scherer, S. W., Margalit, H., and Kerem, B. (2003). Molecular basis for expression of common and rare fragile sites. Mol. Cell Biol. 23, 7143-7151.
222. Zou, M., Shi, Y., and Farid, N. R. (1994). Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer 73, 176-180.
223. Zou, W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263-274.